KOMP logo

KOMPSPDR S&P Kensho New Economies Composite ETF

$70.47
$3.00
(4.45%)
Today
Closed $70.47
$0.00
(0.00%)
After Hours
Updated: 06:56 PM EDT
Vol81,996.00
52W High$75.61
52W Low$51.19
50

Neutral Sentiment

How do you feel about KOMP?

News
all
press releases
XPEV Pops, LI Drops After Earnings: XPeng’s Cost Cuts Outshine Li Auto Discounts
Both XPeng and Li Auto reported a double-digit year-on-year decline in revenue, while still exceeding Wall Street expectations.
Stocktwits
News Placeholder
More News
News Placeholder
NRGV Stock Clocks Best Week In 8 Months: Retail Cheers 'Fruitful' Long-Term Investment
Energy Vault Holdings has surged nearly 31% last week, driven by investor optimism over its new projects and a strong future outlook.
Stocktwits
News Placeholder
OCGN Stock Tanks After Gene Therapy Trial Update — What Did Ocugen Announce?
Ocugen said 12-month Phase 2 trial data showed its drug OCU410 significantly reduced lesion growth at the dose planned for Phase 3.
Stocktwits
News Placeholder
Why Is UMAC Stock Falling Today?
Unusual Machines stated that it will issue 8.8 million shares at $17 apiece, a discount of more than 9% to the stock’s closing price on Thursday.
Stocktwits
News Placeholder
Red Cat Stock Slips As Q4 Loss Misses Estimates
The company’s net loss per share of $0.17 during the quarter missed analysts’ estimate of loss per share of $0.15.
Stocktwits
News Placeholder
Why Did DLO Stock Jump After-Hours Today?
DLO’s Total Payment Volume reached a record $13.1 billion in the fourth quarter, up 70% year-over-year.
Stocktwits
News Placeholder
Eastman Kodak Stock Rallies After-Hours As Q4 Revenue Jumps On Strong Segment Performance
Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%.
Stocktwits
News Placeholder
GRRR Shares Gain After-Hours On Breaching $100M Annual Revenue Mark — Retail Says Stock ‘Very Cheap’
Revenue for the year ended Dec. 31, 2025, grew 35.7% to $101.4 million, compared to analysts’ expectations of $99.68 million in revenue.
Stocktwits
News Placeholder
Why Did QURE Stock Almost Halve Pre-Market Today?
uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.
Stocktwits
News Placeholder
Why Did NGNE Stock Surge 25% In Pre-Market Today?
The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.